Here’s what investors need to know.Mangoceuticals shares are powering higher. Why is MGRX stock surging?TRT Sales Surge 336%Since launching in mid-December, month-over-month sales for the injectable TRT program have climbed 336%, while customer acquisition costs have fallen 54%, the company said in an update. Management expects TRT to be the primary growth driver as MangoRx expands both injectable and oral options, including its PRIME capsule, powered by Kyzatrex.Telehealth Platform Targets Growing TRT Mark ...

Danaher Corporation has agreed to acquire Masimo in a cash deal worth $9.9bn in an effort to broaden its diagnostics business in the telehealth space. Under the deal, which is valued at a price per share of $180, Danaher said that Masimo will become a standalone business unit and brand within its diagnostics unit, operating autonomously while strengthening the life science conglomerate’s offering in acute care settings. Pending customary closing conditions, the transaction is expected to complete in H2 20 ...

Pre-Fulfillment Prescribing Now Available in All 50 States, Supporting National LaunchDeveloped and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in 10–15 minutes, and improve arousal sensations based on clinically-validated endpoints. Market introduction of DARE to PLAY™ is expected to mark a breakthrough in women’s sexual health and represents important prog ...

ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCID: MAJI), a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, is pleased to announce a significant acceleration in its healthcare vertical with the execution of a third Letter of Intent (LOI) to acquire an established telehealth organization. Strategic Infrastructure & Direct-to-Patient Network This third acquisition represents a cornerstone in Exousia’s strategy to build a vertically integ ...

The vast majority of individuals using remote GP services through their insurer are satisfied with the service received, as per a GlobalData survey. These services have become a commodity in both travel and private medical insurance policies and can be a differentiating factor among competitors who withdraw this benefit. According to GlobalData’s 2025 UK Insurance Consumer Survey, 37.3% of private medical insurance policyholders have previously used the remote / video GP consultation feature offered by t ...

Core Insights - The article discusses the growing consumer interest in telehealth platforms for prescription weight management treatments, particularly through PharmaZee, which connects patients with licensed clinicians for evaluations and prescriptions [5][9][21]. Group 1: Company Overview - PharmaZee operates as a telehealth platform that facilitates access to prescription weight management medications through evaluations by U.S.-licensed physicians [4][21]. - The platform provides compounded semaglutide formulations, which are prepared by licensed pharmacies and are not FDA-approved finished products [22][24]. - PharmaZee emphasizes that it is not a healthcare provider but a technology platform that connects patients with medical professionals [23]. Group 2: Market Context - Novo Nordisk raised concerns about "illegal mass compounding" and "deceptive advertising" in the GLP-1 telehealth market, highlighting issues consumers face when researching compounded GLP-1 access [7][8]. - There is an increasing trend of consumers researching telehealth-based weight management medications, indicating a shift in how individuals approach weight management options [5][9]. Group 3: Consumer Considerations - Consumers evaluating GLP-1 telehealth platforms consider factors such as clinician licensing, prescription approval clarity, and whether the platform provides FDA-approved medications or compounded formulations [16][20]. - Transparency regarding contraindications, ongoing medical supervision, and pharmacy sourcing standards are critical factors for consumers when choosing a telehealth service [18][19]. Group 4: Regulatory and Clinical Insights - GLP-1 receptor agonist medications, such as semaglutide and tirzepatide, require physician evaluation and ongoing medical supervision, with specific contraindications outlined by the FDA [12][27][28]. - The distinction between FDA-approved medications and compounded formulations is crucial for consumers to understand, as compounded medications are not subject to the same regulatory scrutiny [24][25].

Group 1 - Medicare is ending broad coverage for telehealth services starting January 31, with exceptions primarily for rural areas and medical facility visits [1] - Teladoc Health experienced significant growth during the early pandemic as it provided essential telehealth services, leading to increased revenue and stock price [3] - The acquisition of Livongo aimed to enhance Teladoc's offerings but was made at high valuations, and the reopening of medical offices introduced competition from traditional healthcare providers and new entrants like Amazon [4] Group 2 - Teladoc's revenue has declined, and the company has struggled to achieve profitability, resulting in a stock price drop of over 70% in the past three years [5] - Despite the changes in Medicare coverage, Teladoc's revenue is primarily derived from commercial customers, particularly large enterprises and health plans, which may mitigate the impact of the Medicare shift on its growth [6]

Core Insights - Telehealth services offer convenience and potential savings for both physicians and patients, yet companies like Teladoc Health and Doximity have struggled in recent years [1][2] Group 1: Telehealth Market Dynamics - Medicare's reimbursement for telehealth services is set to expire on January 31, limiting coverage to specific cases, which is expected to reduce demand for telehealth [5][8] - The early pandemic years saw increased accessibility to telemedicine, but the upcoming changes in Medicare policy may reverse some of these gains [4] Group 2: Company Performance Outlook - Teladoc is anticipated to experience continued weak performance in 2026, with slow revenue growth and ongoing profitability challenges, exacerbated by the Medicare changes [6][7] - Doximity, while less affected by Medicare changes due to its broader service offerings, still faces a dim outlook in the current market environment [8][10] - Teladoc's international expansion shows some promise, but the company faces significant challenges that may hinder its recovery [9]

Core Insights - CISO Global, Inc. has formed a strategic partnership with TeleDental.com and DentalChat.com to provide CyberSimple powered by CHECKLIGHT, a cybersecurity solution tailored for dental practices [1][2] Group 1: Partnership and Market Potential - The collaboration will initially extend cybersecurity protection to over 358 dental clinics across the U.S., with significant potential for expansion in the dental market [2] - There are approximately 190,000 dental practices in the U.S., representing a total addressable market (TAM) of around $350 million annually for cybersecurity solutions tailored to dental clinics [3] Group 2: Product Offering - CyberSimple powered by CHECKLIGHT offers up to $1.5 million in financial protection against cyberattacks, ransomware, and data breaches, while ensuring compliance with HIPAA and safeguarding patient protected health information (PHI) [4] - The platform integrates continuous monitoring, threat detection, incident response, and financial risk mitigation, allowing dental professionals to focus on patient care rather than cybersecurity management [6] Group 3: Industry Context - Dental practices are increasingly targeted by cybercriminals due to limited IT resources and the high value of patient data, necessitating effective cybersecurity solutions [5] - The partnership addresses the growing cyber threats faced by dental practices, providing a simplified and scalable cybersecurity solution [7]

Core Viewpoint - LifeMD, Inc. has expanded its virtual weight management offerings by introducing Novo Nordisk's Wegovy pill, the first FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health, available for eligible patients at a starting price of $149 per month [1][5]. Group 1: Product Offering - LifeMD is now offering Wegovy (semaglutide) through its telehealth platform, enhancing access to affordable branded treatment options for weight management [1]. - Wegovy is indicated for reducing excess body weight, supporting long-term weight maintenance, and lowering the risk of major adverse cardiovascular events, with a Phase 3 trial showing a mean weight loss of 16.6% compared to 2.7% with placebo [3]. - The oral formulation of Wegovy is expected to attract patients who are hesitant to use injectable treatments, thereby broadening access to GLP-1 therapies [3]. Group 2: Collaboration and Integration - LifeMD's collaboration with Novo Nordisk is highlighted, with LifeMD being featured as a trusted telehealth provider on NovoCare and Wegovy websites, reflecting the demand for convenient access to GLP-1 therapies [2]. - The integration with NovoCare Pharmacy allows streamlined access to both injectable and oral GLP-1 medications, including Wegovy and Ozempic, at competitive cash-pay pricing [4]. - LifeMD provides a comprehensive experience that includes virtual visits, ongoing clinical oversight, diagnostic testing, pharmacy fulfillment, and simplified billing [4]. Group 3: Pricing and Availability - Wegovy 1.5mg and 4mg pills are available for $149 per month, with future pricing adjustments planned for April 15, 2026, where 4mg will be priced at $199 and higher doses at $299 per month [5].